Business Context and Reporting Period
This Form 8-K Current Report from Alnylam Pharmaceuticals, Inc. covers the period ending March 31, 2022, with the report filed on April 5, 2022. The filing primarily addresses corporate governance changes regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel and governance rather than financial performance.
Material Changes
- Board Resignation: Steven M. Paul, M.D., resigned from the Board of Directors effective April 16, 2022.
- Board Size Reduction: The Board approved a reduction in size from eleven to ten members, effective upon Dr. Paul's resignation.
- Committee Appointment: Colleen F. Reitan was appointed to the People, Culture and Compensation (PC&C) Committee upon Dr. Paul's departure.
- Committee Leadership: Amy W. Schulman continues as Chair of the PC&C Committee, and Olivier Brandicourt remains a member.
Management Commentary and Risks
Management stated that Dr. Paul's resignation was not caused by any disagreement with the Company regarding its operations, policies, or practices. A press release announcing the retirement was issued on April 5, 2022. No specific financial risks, contingencies, or unusual items were disclosed in this filing.
Key Facts for Investor Verification
- Confirm the effective date of Dr. Paul's resignation (April 16, 2022) and the resulting Board composition.
- Verify the updated membership of the People, Culture and Compensation Committee.
- Review the attached press release (Exhibit 99.1) for additional context on the retirement.